Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06689839 · ClinicalTrials.gov registry record · NA

Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR

A NA study of Aortic Diseases and Aortic Stenosis Treated With TAVI, sponsored by EnCompass Technologies.

Recruiting
Registry status
NA
Development phase
500
Enrollment target
10
Study locations

NCT06689839 is a NA study of Aortic Diseases and Aortic Stenosis Treated With TAVI that is actively recruiting participants, run by EnCompass Technologies. The registered enrollment target is 500 participants, below the 1,481-participant average among 7 other Aortic Diseases trials with a reported enrollment target (66% lower). The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06689839, a NA study of Aortic Diseases and Aortic Stenosis Treated With TAVI, is actively recruiting participants, sponsored by EnCompass Technologies.

RECRUITING
Registry status
NA
Development phase
500 participants
Enrollment target
10
Study locations

Study Summary

The objective of this study is to compare the safety and effectiveness of the F2 Cerebral Protection System (CPS) to a standard of care control group in patients undergoing Transcatheter Aortic Valve Replacement (TF TAVR)

Conditions Studied

Aortic Diseases Aortic Stenosis Treated With TAVI

Interventions

  • DEVICE F2 Filter and Delivery System
  • PROCEDURE Transcatheter Aortic Valve Replacement (TAVR)

Study Locations (10)

Ohio

  • Cleveland Clinic Foundation - Cleveland
  • Ohio Health Research Institute (aka Riverside Methodist Hospital) - Columbus

Florida

  • NCH Baker Hospital-Naples Heart Institute - Naples

Indiana

  • St. Vincent Hospital - Indianappolis

Michigan

  • Henry Ford Hospital - Detroit

Missouri

  • St. Lukes Hospital Of Kansas City - Kansas City

New York

  • Cumc/Nyph - New York

Virginia

  • University of Virginia Medical Center - Charlottesville

Queensland

  • St Andrews War Memorial Hospital - Spring Hill

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2025-09-09
Est. Completion 2027-01
Phase NA

Sponsor

EnCompass Technologies

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06689839

The ClinicalTrials.gov registry entry for NCT06689839 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,481-participant average among 7 other Aortic Diseases trials with a reported enrollment target (66% lower). The listed sponsor is EnCompass Technologies, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Aortic Diseases appearing as the primary indexed condition, and to 2 interventions - of which F2 Filter and Delivery System is the first listed.

NCT06689839 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Ohio, Florida, Indiana.

Frequently Asked Questions

What is clinical trial NCT06689839 about?

NCT06689839 is a clinical study titled "Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR". The objective of this study is to compare the safety and effectiveness of the F2 Cerebral Protection System (CPS) to a standard of care control group in patients undergoing Transcatheter Aortic Valve Replacement (TF TAVR)

What is the current status of trial NCT06689839?

This trial is currently recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2025-09-09. Estimated completion is 2027-01.

What conditions does trial NCT06689839 study?

This clinical trial studies the following conditions: Aortic Diseases, Aortic Stenosis Treated With TAVI.

What interventions are being tested in trial NCT06689839?

The interventions under investigation include: F2 Filter and Delivery System (DEVICE), Transcatheter Aortic Valve Replacement (TAVR) (PROCEDURE).

Who is sponsoring clinical trial NCT06689839?

This trial is sponsored by EnCompass Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06689839 being conducted?

This trial has 10 study locations across Florida, Indiana, Michigan, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Aortic Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Aortic Diseases

All registered trials for this condition

Aortic Stenosis Treated With TAVI

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.